ABCB5 and epidermolysis bullosa: A recent trial evaluating intravenously injected ABCB5+ allogeneic skin-derived hMSCs in patients with epidermolysis bullosa reported two patients with severe, yet transient and manageable, hypersensitivity reactions (11).